Foghorn Therapeutics Inc

FHTX remains in a prolonged Stage 4 decline under sustained lower highs and lower lows with EMAs sloping downward and acting as resistance. The active Bearish Exhaustion pattern signals sellers losing control and increases the probability of a bottoming attempt or reversal bounce. Despite extreme oversold readings, lack of sustained reversal suggests selling is best deferred. Favor trimming on rallies into declining EMA regions or prior support-turned-resistance zones for structurally aligned execution.

• ↑Analyst price target $11.44 implies ~90% upside from $6.01
• ↑Return on equity at 85.8% indicates robust capital returns
• ↓Q2 revenue $3.27 M vs $7.94 M estimate highlights sales shortfall